Выпуск
Daily Briefing for November 9, 2026
Physician in the Loop · 9 ноября 2026 г. · 5 мин
Stopping statins after 70 meets noninferiority but adds 1 event per 40 patients The voices on this episode are generated, and so is the script, from the day's post at Physician in the Loop. Every fact in the post links to its source. Read the post and its sources Get the free email briefing Adults 70 and older who stopped primary-prevention statins had more heart attacks, strokes and deaths, but within a preset noninferiority margin, a 1,880-patient trial reported Nov. 7 in the New England Journal of Medicine. The STREAM trial enrolled people 70 and older with at least two chronic conditions and no known atherosclerotic disease, and the investigators estimated one additional major cardiovascular event or death over two years for every 40 people who stopped, according to HCPLive . Study author Dr. Rita Redberg called for shared decision-making rather than a blanket recommendation to stop, the report said. Also at the American Heart Association's Scientific Sessions, Cleerly reported that its AI analysis of coronary CT beat stress-test-guided care at 180 days in a randomized trial whose results have not been peer reviewed. The Food and Drug Administration asked for feedback on robotic devices that act on their own or are run from a distance, and a 1,706-patient trial in Colombia and Jamaica found single-pill combination therapy with team-based care cut systolic pressure 10.1 mm Hg more than usual care. In this episode Stopping statins in adults 70 and older without heart disease met noninferiority in a 1,880-patient trial, though events rose to 12.7% from 9.2% AI plaque analysis on coronary CT beat stress-test-guided care at 180 days in a 530-patient trial, the company reports FDA asks how to weigh the benefits and risks of robots that operate on their own or are run from afar Single-pill combinations delivered through team-based care cut systolic pressure 10.1 mm Hg more than usual care in a 1,706-patient trial FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer after platinum and immunotherapy, with a 42% response rate